Relmada Therapeutics, Inc. · Brief

Next report

10 days

Nov 12 · after closeest.Q3 FY26

Expected move

±9.9%implied · report alone

3.233.93

straddle ±27.3%

spot 3.58exp Nov 20ATM strike 2.5ATM straddle 1.15IV 71%

Oct 30 closereport share · term structure

Expected move

—≥ implied

Q2 FY26±12.8%▼−8.01%×0.63

quarterimplied−15%0+15%realized×

Q2 FY26±12.8%▼−8.01%×0.63

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 12 report · est.

Bull2

126managers reporting a position in the latest quarterly filings13F · Jun 30 '26

+41.63%change in shares held by the ten largest reporting managers over the latest quarter13F · Jun 30 '26

Bear2

23managers holding four fifths of reported value13F · Jun 30 '26

6 of 23of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

AI captions · Oct 26 '26once per report · top 2 per case

RLMD report session

No linked exposure.

Oct 29impliedImplied move: ±24.7% into Nov 12 earnings (Oct 29 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.